ENOB - Enochian Biosciences: Small Biotech With Ambitious Goals In HIV And HBV

• Enochian Biosciences is tackling some difficult areas of biotech with innovative treatment types.
• The company is attempting to develop a cure for HIV, Hepatitis B and extending remission in difficult to treat cancers including pancreatic cancer.
• None of the company's assets have entered the clinic but several data readouts are expected this year, leading to potential IND submissions.
• The company's executive vice chairman has had a distinguished career in public health and Enochian has built an apparently strong network of collaborators.
• At $3 per share at the time of writing and a market cap of $140, I see share price accretion - shares traded at $4.5 as recently as February.

For further details see: